{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:26:59Z","timestamp":1784690819973,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["701136"],"award-info":[{"award-number":["701136"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Uehara Memorial Foundation Research Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multimodal radio-chemotherapy is the mainstay of treatment for unresectable thymoma (TH) and thymic carcinoma (TC), but there is an urgent need for other therapeutic strategies in these rare tumors. The epithelial cells of the normal thymus express the three major proteasome classes: constitutive, immunoproteasome, and thymoproteasome, making thymic epithelial tumors potential candidates for treatment with proteasome inhibitors. In a drug screen of 120 cytotoxic agents, the two thymic carcinoma cell lines 1889c and MP57 showed exquisite sensitivity to the proteasome inhibitor carfilzomib (PR-171). Immunohistochemistry, gene expression, and in vitro functional studies were used in a comprehensive sample collection to investigate the correlation between immunoproteasome subunit expression and response to carfilzomib. 50% of TC and a substantial proportion of TH strongly expressed immunoproteasome subunits and showed functional activity of \u03b21i (PSMB9), \u03b22i (PSMB10), and \u03b25i (PSMB8). INF-\u03b3 treatment induced immunoproteasome expression and increased cell sensitivity to carfilzomib, while siRNA knockdown reduced carfilzomib response in vitro. Carfilzomib synergized with BCL2 family protein inhibitors (navitoclax or AZD5991), suggesting that drug combinations could be used to reduce the dose of each drug to minimize toxicity. Notably, thymic carcinomas differed from squamous cell carcinomas in other organs by higher levels of \u03b25i (PSMB8) and constitutive proteasome \u03b25 (PSMB5). We hypothesize that TC (and probably many TH) are uniquely suited for treatment with proteasome inhibitors alone or in combination with selective BH3 mimetics.<\/jats:p>","DOI":"10.1038\/s41419-025-08240-5","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:55:35Z","timestamp":1764820535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proteasome inhibition as a potential therapeutic target in thymic cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-3587","authenticated-orcid":false,"given":"Satoru","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Benter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Schrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4006-4369","authenticated-orcid":false,"given":"Selen","family":"Selcen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanibal","family":"Bohnenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-4508","authenticated-orcid":false,"given":"G\u00fcnter","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-3292","authenticated-orcid":false,"given":"Melanie","family":"Lohrberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-0171","authenticated-orcid":false,"given":"Tobias R.","family":"Overbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"von Hammerstein-Equord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Welter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hinterthaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Cordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoon","family":"Shirneshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Netzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-2483","authenticated-orcid":false,"given":"Alexander","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-8060","authenticated-orcid":false,"given":"Philipp","family":"Str\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8443-601X","authenticated-orcid":false,"given":"Stefan","family":"K\u00fcffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"8240_CR1","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","volume":"10","author":"A Marx","year":"2015","unstructured":"Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, et al. The 2015 World Health Organization classification of tumors of the thymus: continuity and changes. J Thorac Oncol. 2015;10:1383\u201395.","journal-title":"J Thorac Oncol"},{"key":"8240_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","volume":"33","author":"M Radovich","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell. 2018;33:244\u201358.e10.","journal-title":"Cancer Cell"},{"key":"8240_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/cancers16010166","volume":"16","author":"S Barachini","year":"2023","unstructured":"Barachini S, Pardini E, Burzi IS, Sardo Infirri G, Montali M, Petrini I. Molecular and functional key features and oncogenic drivers in thymic carcinomas. Cancers (Basel). 2023;16:166.","journal-title":"Cancers (Basel)"},{"key":"8240_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19:347\u201355.","journal-title":"Lancet Oncol"},{"key":"8240_CR5","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"J Cho","year":"2019","unstructured":"Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37:2162\u201370.","journal-title":"J Clin Oncol"},{"key":"8240_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-6-73","volume":"6","author":"J Voortman","year":"2007","unstructured":"Voortman J, Checinska A, Giaccone G. The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer. 2007;6:73.","journal-title":"Mol Cancer"},{"key":"8240_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01622-9","volume":"21","author":"H Wang","year":"2022","unstructured":"Wang H, Yang W, Qin Q, Yang X, Yang Y, Liu H, et al. E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer. Mol Cancer. 2022;21:151.","journal-title":"Mol Cancer"},{"key":"8240_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.06.037","volume":"11","author":"X Zhou","year":"2024","unstructured":"Zhou X, Xu R, Wu Y, Zhou L, Xiang T. The role of proteasomes in tumorigenesis. Genes Dis. 2024;11:101070.","journal-title":"Genes Dis"},{"key":"8240_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cbpa.2008.06.033","volume":"12","author":"BS Moore","year":"2008","unstructured":"Moore BS, Eustaquio AS, McGlinchey RP. Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol. 2008;12:434\u201340.","journal-title":"Curr Opin Chem Biol"},{"key":"8240_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/541984","volume":"2015","author":"H Kimura","year":"2015","unstructured":"Kimura H, Caturegli P, Takahashi M, Suzuki K. New insights into the function of the immunoproteasome in immune and nonimmune cells. J Immunol Res. 2015;2015:541984.","journal-title":"J Immunol Res"},{"key":"8240_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2024.106899","volume":"269","author":"M Mishto","year":"2024","unstructured":"Mishto M, Takala I, Bonfanti P, Liepe J. Proteasome isoforms in human thymi and mouse models. Immunol Lett. 2024;269:106899.","journal-title":"Immunol Lett"},{"key":"8240_CR12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1097\/PAS.0b013e3182237f5d","volume":"35","author":"Y Yamada","year":"2011","unstructured":"Yamada Y, Tomaru U, Ishizu A, Kiuchi T, Marukawa K, Matsuno Y, et al. Expression of proteasome subunit beta5t in thymic epithelial tumors. Am J Surg Pathol. 2011;35:1296\u20131304.","journal-title":"Am J Surg Pathol"},{"key":"8240_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/his.12279","volume":"64","author":"P Strobel","year":"2014","unstructured":"Strobel P, Hartmann E, Rosenwald A, Kalla J, Ott G, Friedel G, et al. Corticomedullary differentiation and maturational arrest in thymomas. Histopathology. 2014;64:557\u201366.","journal-title":"Histopathology"},{"key":"8240_CR14","doi-asserted-by":"publisher","first-page":"e151353","DOI":"10.1172\/jci.insight.151353","volume":"7","author":"F Orben","year":"2022","unstructured":"Orben F, Lankes K, Schneeweis C, Hassan Z, Jakubowsky H, Krauss L, et al. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. JCI Insight. 2022;7:e151353.","journal-title":"JCI Insight"},{"key":"8240_CR15","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/ijc.23335","volume":"122","author":"V Ehemann","year":"2008","unstructured":"Ehemann V, Kern MA, Breinig M, Schnabel PA, Gunawan B, Schulten HJ, et al. Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. Int J Cancer. 2008;122:2719\u201325.","journal-title":"Int J Cancer"},{"key":"8240_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","volume":"11","author":"AT Alberobello","year":"2016","unstructured":"Alberobello AT, Wang Y, Beerkens FJ, Conforti F, McCutcheon JN, Rao G, et al. PI3K as a potential therapeutic target in thymic epithelial tumors. J Thorac Oncol. 2016;11:1345\u201356.","journal-title":"J Thorac Oncol"},{"key":"8240_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02158-3","volume":"19","author":"D Muller","year":"2021","unstructured":"Muller D, Mazzeo P, Koch R, Bosherz MS, Welter S, von Hammerstein-Equord A, et al. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas. BMC Med. 2021;19:300.","journal-title":"BMC Med"},{"key":"8240_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1182\/blood-2018-07-865527","volume":"133","author":"R Koch","year":"2019","unstructured":"Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, et al. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019;133:566\u201375.","journal-title":"Blood"},{"key":"8240_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/cdd.2017.183","volume":"25","author":"J Montero","year":"2018","unstructured":"Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25:56\u201364.","journal-title":"Cell Death Differ"},{"key":"8240_CR20","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1002\/anie.201509092","volume":"55","author":"G de Bruin","year":"2016","unstructured":"de Bruin G, Xin BT, Kraus M, van der Stelt M, van der Marel GA, Kisselev AF, et al. A set of activity-based probes to visualize human (immuno)proteasome activities. Angew Chem Int Ed Engl. 2016;55:4199\u2013203.","journal-title":"Angew Chem Int Ed Engl"},{"key":"8240_CR21","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/cancers16152762","volume":"16","author":"D Muller","year":"2024","unstructured":"Muller D, Loskutov J, Kuffer S, Marx A, Regenbrecht CRA, Strobel P, et al. Cell culture models for translational research on thymomas and thymic carcinomas: current status and future perspectives. Cancers (Basel). 2024;16:2762.","journal-title":"Cancers (Basel)"},{"key":"8240_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jconrel.2019.04.006","volume":"302","author":"JE Park","year":"2019","unstructured":"Park JE, Park J, Jun Y, Oh Y, Ryoo G, Jeong YS, et al. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. J Control Release. 2019;302:148\u201359.","journal-title":"J Control Release"},{"key":"8240_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clml.2018.08.016","volume":"19","author":"X Leleu","year":"2019","unstructured":"Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, et al. Role of proteasome inhibitors in relapsed and\/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19:9\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"8240_CR24","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-21-0344","volume":"28","author":"S Majeed","year":"2022","unstructured":"Majeed S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, Rahman F, Song L, et al. Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small-cell lung cancer. Clin Cancer Res. 2022;28:1966\u201378.","journal-title":"Clin Cancer Res"},{"key":"8240_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","volume":"22","author":"JJ Shah","year":"2016","unstructured":"Shah JJ, Jakubowiak AJ, O\u2019Connor OA, Orlowski RZ, Harvey RD, Smith MR, et al. Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma. Clin Cancer Res. 2016;22:34\u201343.","journal-title":"Clin Cancer Res"},{"key":"8240_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10637-016-0348-5","volume":"34","author":"S Bhatia","year":"2016","unstructured":"Bhatia S, Pavlick AC, Boasberg P, Thompson JA, Mulligan G, Pickard MD, et al. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924\/MLN4924) in patients with metastatic melanoma. Invest N. Drugs. 2016;34:439\u201349.","journal-title":"Invest N. Drugs"},{"key":"8240_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1078-0432.CCR-15-1338","volume":"22","author":"J Sarantopoulos","year":"2016","unstructured":"Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, et al. Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924\/MLN4924) in patients with advanced solid tumors. Clin Cancer Res. 2016;22:847\u201357.","journal-title":"Clin Cancer Res"},{"key":"8240_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09775-y","volume":"22","author":"A Salimi","year":"2022","unstructured":"Salimi A, Schroeder KM, Schemionek-Reinders M, Vieri M, Maletzke S, Gezer D, et al. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK. BMC Cancer. 2022;22:735.","journal-title":"BMC Cancer"},{"key":"8240_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1083\/jcb.201210077","volume":"199","author":"AL Goldberg","year":"2012","unstructured":"Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol. 2012;199:583\u20138.","journal-title":"J Cell Biol"},{"key":"8240_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbrc.2007.07.020","volume":"361","author":"C Guinez","year":"2007","unstructured":"Guinez C, Mir AM, Leroy Y, Cacan R, Michalski JC, Lefebvre T. Hsp70-GlcNAc-binding activity is released by stress, proteasome inhibition, and protein misfolding. Biochem Biophys Res Commun. 2007;361:414\u201320.","journal-title":"Biochem Biophys Res Commun"},{"key":"8240_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mcn.2013.11.001","volume":"58","author":"L Agholme","year":"2014","unstructured":"Agholme L, Nath S, Domert J, Marcusson J, Kagedal K, Hallbeck M. Proteasome inhibition induces stress kinase dependent transport deficits-implications for Alzheimer\u2019s disease. Mol Cell Neurosci. 2014;58:29\u201339.","journal-title":"Mol Cell Neurosci"},{"key":"8240_CR32","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.1002\/jcp.26516","volume":"233","author":"T Fan","year":"2018","unstructured":"Fan T, Huang Z, Wang W, Zhang B, Xu Y, Mao Z, et al. Proteasome inhibition promotes autophagy and protects from endoplasmic reticulum stress in rat alveolar macrophages exposed to hypoxia-reoxygenation injury. J Cell Physiol. 2018;233:6748\u201358.","journal-title":"J Cell Physiol"},{"key":"8240_CR33","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/sj.embor.7400779","volume":"7","author":"E Szegezdi","year":"2006","unstructured":"Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006;7:880\u20135.","journal-title":"EMBO Rep."},{"key":"8240_CR34","doi-asserted-by":"publisher","first-page":"17682","DOI":"10.1074\/jbc.M110.189092","volume":"286","author":"AJ Smith","year":"2011","unstructured":"Smith AJ, Dai H, Correia C, Takahashi R, Lee SH, Schmitz I, et al. Noxa\/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem. 2011;286:17682\u201392.","journal-title":"J Biol Chem"},{"key":"8240_CR35","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/cancers13061235","volume":"13","author":"T Paradzik","year":"2021","unstructured":"Paradzik T, Bandini C, Mereu E, Labrador M, Taiana E, Amodio N, et al. The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma. Cancers (Basel). 2021;13:1235.","journal-title":"Cancers (Basel)"},{"key":"8240_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/1078-0432.CCR-08-1612","volume":"15","author":"G Bisping","year":"2009","unstructured":"Bisping G, Wenning D, Kropff M, Gustavus D, Muller-Tidow C, Stelljes M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res. 2009;15:520\u201331.","journal-title":"Clin Cancer Res"},{"key":"8240_CR37","unstructured":"NCCN Thymoma and Thymic Carcinoma Version 1.2023. (National Comprehensive Cancer NetworkR.) 2022."},{"key":"8240_CR38","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3390\/cancers16050942","volume":"16","author":"S Kuffer","year":"2024","unstructured":"Kuffer S, Muller D, Marx A, Strobel P. Non-mutational key features in the biology of thymomas. Cancers (Basel). 2024;16:942.","journal-title":"Cancers (Basel)"},{"key":"8240_CR39","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2147\/CMAR.S150653","volume":"11","author":"K Groen","year":"2019","unstructured":"Groen K, van de Donk N, Stege C, Zweegman S, Nijhof IS. Carfilzomib for relapsed and refractory multiple myeloma. Cancer Manag Res. 2019;11:2663\u201375.","journal-title":"Cancer Manag Res"},{"key":"8240_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","volume":"26","author":"A Besse","year":"2019","unstructured":"Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin BT, et al. Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors. Cell Chem Biol. 2019;26:340\u201351.e3.","journal-title":"Cell Chem Biol"},{"key":"8240_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111428","volume":"40","author":"M Oron","year":"2022","unstructured":"Oron M, Grochowski M, Jaiswar A, Legierska J, Jastrzebski K, Nowak-Niezgoda M, et al. The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells. Cell Rep. 2022;40:111428.","journal-title":"Cell Rep."},{"key":"8240_CR42","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.2174\/1381612811319220018","volume":"19","author":"Z Miller","year":"2013","unstructured":"Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des. 2013;19:4140\u201351.","journal-title":"Curr Pharm Des"},{"key":"8240_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/cncr.23224","volume":"112","author":"A Busse","year":"2008","unstructured":"Busse A, Kraus M, Na IK, Rietz A, Scheibenbogen C, Driessen C, et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer. 2008;112:659\u201370.","journal-title":"Cancer"},{"key":"8240_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep34019","volume":"6","author":"A Rouette","year":"2016","unstructured":"Rouette A, Trofimov A, Haberl D, Boucher G, Lavallee VP, D\u2019Angelo G, et al. Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers. Sci Rep. 2016;6:34019.","journal-title":"Sci Rep."},{"key":"8240_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1756-8722-7-7","volume":"7","author":"D Niewerth","year":"2014","unstructured":"Niewerth D, Kaspers GJ, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, et al. Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol. 2014;7:7.","journal-title":"J Hematol Oncol"},{"key":"8240_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fonc.2016.00219","volume":"6","author":"SA Dooley","year":"2016","unstructured":"Dooley SA, Anderson CM. Definitive IMRT for Stage III thymic carcinoma: a brief report and literature review. Front Oncol. 2016;6:219.","journal-title":"Front Oncol"},{"key":"8240_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.735466","volume":"8","author":"Y Zhai","year":"2021","unstructured":"Zhai Y, Ye X, Hu F, Xu J, Guo X, Cao Y, et al. Cardiovascular toxicity of carfilzomib: the real-world evidence based on the adverse event reporting system database of the FDA, the United States. Front Cardiovasc Med. 2021;8:735466.","journal-title":"Front Cardiovasc Med"},{"key":"8240_CR48","first-page":"3280","volume":"12","author":"T Kubicki","year":"2022","unstructured":"Kubicki T, Bednarek K, Kostrzewska-Poczekaj M, Luczak M, Lewandowski K, Gil L, et al. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response. Am J Cancer Res. 2022;12:3280\u201393.","journal-title":"Am J Cancer Res"},{"key":"8240_CR49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","volume":"72","author":"KP Papadopoulos","year":"2013","unstructured":"Papadopoulos KP, Burris HA 3rd, Gordon M, Lee P, Sausville EA, et al. A phase I\/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharm. 2013;72:861\u20138.","journal-title":"Cancer Chemother Pharm"},{"key":"8240_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-014-0094-0","volume":"12","author":"RJ Deshaies","year":"2014","unstructured":"Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014;12:94.","journal-title":"BMC Biol"},{"key":"8240_CR51","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/cancers12051207","volume":"12","author":"MA Harris","year":"2020","unstructured":"Harris MA, Miles MA, Shekhar TM, Cerra C, Georgy SR, Ryan SD, et al. The proteasome inhibitor ixazomib inhibits the formation and growth of pulmonary and abdominal osteosarcoma metastases in mice. Cancers (Basel). 2020;12:1207.","journal-title":"Cancers (Basel)"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08240-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08240-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08240-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:02:25Z","timestamp":1765468945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08240-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8240"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08240-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Medical Faculty Mannheim, University of Heidelberg (2013-802R-MA) and University Medical Center G\u00f6ttingen (G\u00d6 912\/15).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"All subjects have written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"885"}}